Pancreatic Cancer Research

ResearcherSaiseikai Fukuoka General HospitalActive in the last 2 years

Takashi Morisaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-3642-1656; OpenAlex author ID A5103690127. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 7

  1. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Last author DOI 10.3389/fimmu.2025.1571182↗
  2. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  3. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  4. TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15205↗
  5. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Co-author DOI 10.1097/cji.0000000000000305↗
  6. Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line. Co-author PMID 26851020↗
  7. Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxi… Co-author DOI 10.1016/j.canlet.2013.02.041↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hideya Onishi · 6 shared papers, 2013–2025 · strength 0.68
  2. Chika Iwamoto · 3 shared papers, 2024–2025 · strength 0.51
  3. Kohei Nakata · 3 shared papers, 2024–2025 · strength 0.51
  4. Toshiya Abe · 3 shared papers, 2024–2025 · strength 0.51
  5. Koki Oyama · 3 shared papers, 2024–2025 · strength 0.51
  6. Naoki Ikenaga · 3 shared papers, 2024–2025 · strength 0.51
  7. Kenoki Ohuchida · 3 shared papers, 2020–2024 · strength 0.41
  8. Yoshinao Oda · 2 shared papers, 2024 · strength 0.32
  9. Masataka Hayashi · 2 shared papers, 2024 · strength 0.32
  10. Kazuhiro Koikawa · 2 shared papers, 2024 · strength 0.32
  11. Masafumi Nakamura · 2 shared papers, 2024 · strength 0.32
  12. Haizhen Luo · 2 shared papers, 2024 · strength 0.32
  13. Pingshan Zhong · 2 shared papers, 2024 · strength 0.32
  14. Masafumi Nakamura · 2 shared papers, 2020–2025 · strength 0.30
  15. Yasuhiro Oyama · 2 shared papers, 2020–2021 · strength 0.22
  16. Nao Fujimori · 1 shared paper, 2025 · strength 0.20
  17. Hiroto Tanaka · 1 shared paper, 2025 · strength 0.20
  18. Yusuke Nakamura · 1 shared paper, 2025 · strength 0.20
  19. Akio Yamasaki · 2 shared papers, 2016–2021 · strength 0.19
  20. Makoto Kawamoto · 2 shared papers, 2016–2020 · strength 0.16
  21. Akira Imaizumi · 2 shared papers, 2016–2020 · strength 0.16
  22. Akiko Sagara · 1 shared paper, 2024 · strength 0.16
  23. Chikanori Tsutsumi · 1 shared paper, 2024 · strength 0.15
  24. Noboru Ideno · 1 shared paper, 2024 · strength 0.15
  25. Tomohiko Shinkawa · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.